ResMed Inc. (RMD) CFO Sells $228,360.00 in Stock

ResMed Inc. (NYSE:RMD) CFO Brett Sandercock sold 2,000 shares of ResMed stock in a transaction dated Tuesday, January 15th. The stock was sold at an average price of $114.18, for a total value of $228,360.00. Following the sale, the chief financial officer now directly owns 94,390 shares of the company’s stock, valued at $10,777,450.20. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Brett Sandercock also recently made the following trade(s):

  • On Tuesday, December 31st, Brett Sandercock sold 3,000 shares of ResMed stock. The shares were sold at an average price of $112.50, for a total value of $337,500.00.
  • On Monday, December 31st, Brett Sandercock sold 3,000 shares of ResMed stock. The stock was sold at an average price of $112.50, for a total value of $337,500.00.
  • On Monday, December 17th, Brett Sandercock sold 2,000 shares of ResMed stock. The shares were sold at an average price of $112.56, for a total value of $225,120.00.
  • On Friday, November 30th, Brett Sandercock sold 3,000 shares of ResMed stock. The stock was sold at an average price of $110.50, for a total value of $331,500.00.
  • On Thursday, November 15th, Brett Sandercock sold 2,000 shares of ResMed stock. The shares were sold at an average price of $101.44, for a total value of $202,880.00.

ResMed stock opened at $117.41 on Friday. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.58 and a quick ratio of 1.91. ResMed Inc. has a 52 week low of $87.10 and a 52 week high of $118.13. The company has a market capitalization of $16.48 billion, a P/E ratio of 33.26, a PEG ratio of 2.95 and a beta of 0.86.

ResMed (NYSE:RMD) last released its quarterly earnings data on Thursday, October 25th. The medical equipment provider reported $0.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.80 by $0.01. ResMed had a net margin of 13.94% and a return on equity of 26.29%. The business had revenue of $588.28 million during the quarter, compared to analyst estimates of $576.66 million. Equities analysts forecast that ResMed Inc. will post 3.69 EPS for the current year.

Several hedge funds have recently added to or reduced their stakes in the stock. Cape Cod Five Cents Savings Bank lifted its stake in shares of ResMed by 0.7% in the 4th quarter. Cape Cod Five Cents Savings Bank now owns 36,367 shares of the medical equipment provider’s stock valued at $4,141,000 after purchasing an additional 242 shares during the last quarter. RPG Investment Advisory LLC raised its holdings in ResMed by 0.7% in the 4th quarter. RPG Investment Advisory LLC now owns 48,104 shares of the medical equipment provider’s stock worth $5,478,000 after acquiring an additional 338 shares during the period. First Hawaiian Bank raised its holdings in ResMed by 21.5% in the 4th quarter. First Hawaiian Bank now owns 2,121 shares of the medical equipment provider’s stock worth $241,000 after acquiring an additional 375 shares during the period. CIBC World Markets Inc. raised its holdings in ResMed by 8.2% in the 3rd quarter. CIBC World Markets Inc. now owns 6,528 shares of the medical equipment provider’s stock worth $753,000 after acquiring an additional 493 shares during the period. Finally, Commonwealth Equity Services LLC increased its holdings in shares of ResMed by 10.7% during the 3rd quarter. Commonwealth Equity Services LLC now owns 5,399 shares of the medical equipment provider’s stock worth $622,000 after purchasing an additional 521 shares during the period. 64.86% of the stock is owned by institutional investors and hedge funds.

Several brokerages have recently commented on RMD. BMO Capital Markets raised shares of ResMed from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $109.00 to $127.00 in a research report on Monday, December 10th. Credit Suisse Group upgraded shares of ResMed from a “neutral” rating to an “outperform” rating in a research report on Friday, October 26th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and five have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $123.50.

ILLEGAL ACTIVITY NOTICE: This report was originally published by WKRB News and is the sole property of of WKRB News. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.wkrb13.com/2019/01/18/resmed-inc-rmd-cfo-sells-228360-00-in-stock.html.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.

Further Reading: Asset Allocation

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply